166 related articles for article (PubMed ID: 24750239)
1. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
Ronzoni L; Aghemo A; Rumi MG; Prati G; Colancecco A; Porretti L; Monico S; Colombo M; Cappellini MD
J Viral Hepat; 2014 Jun; 21(6):416-23. PubMed ID: 24750239
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
3. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
4. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
5. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
9. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
[TBL] [Abstract][Full Text] [Related]
10. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
[TBL] [Abstract][Full Text] [Related]
12. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
13. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
[TBL] [Abstract][Full Text] [Related]
14. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C.
Wang LJ; Chen SW; Chen CK; Yen CL; Chang JJ; Lee TS; Liu CJ; Chen LW; Chien RN
BMC Psychiatry; 2016 Nov; 16(1):424. PubMed ID: 27884134
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
Huang CF; Yang JF; Dai CY; Huang JF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Infect Dis; 2010 Mar; 201(5):751-9. PubMed ID: 20102281
[TBL] [Abstract][Full Text] [Related]
18. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
19. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
